Every day patients receive treatments that do not work properly. For many this means no relief from symptoms, but for some death is the result. Yet concerted action against such products is limited. Before we can discuss why that's the case, I will attempt to explain what kind of products don’t work, and what we should call them.

The U.S. Patent and Trademark Office has resisted researchers' overreaching in their patenting of genes, and researchers' work is seldom compromised by patents.

Illegally copying a trademark is an important indicator of counterfeiting, although not necessarily of substandard drug quality.

Scruton makes a counterintuitive yet persuasive case that optimists and idealists--with their ignorance about the truths of human nature and human society, and their naive hopes about what can be changed--have wrought havoc for centuries.

We are at a political impasse in the fight against fake drugs.

Lawmakers need to take a closer look at how to treat fraud at the Patent and Trademark Office.

India's continued rise as a pharmaceutical power is tainted by concerns about fake and substandard drugs, but a new report finds that private companies are finding innovative ways of preserving the identity of their products.

Millions of voters will head to the polls this week for the first phase of what are often called India's second-most important elections -- for a new government in Uttar Pradesh, the country's largest state and home to about one in six of its 1.2 billion citizens. In the drama of Indian democracy, UP has always played a starring role.